• About us
• Contact

Advertisement

Organisation › Details

Embark Biotech (DK)

About Embark Biotech: Embark Biotech is a 2017 spin-out from the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) at University of Copenhagen, where Associate Professor Zach Gerhart-Hines, together with then postdoctoral fellow Jakob Bondo Hansen and Professor Thue W. Schwartz, discovered a novel target that suppresses appetite increases energy expenditure and enhances insulin sensitivity (seed support from Novo Holdings). Development of the target was initiated via an early collaboration with Novo Nordisk. The project was then further matured through support and guidance from the InnoBooster program at the Innovation Fund Denmark and from the BioInnovation Institute (BII) during a residency in the Venture House Program. About Embark Laboratories: Embark Laboratories is a Danish biotech company that focuses on cardiometabolic disease with an emphasis on energy expenditure. All former Embark Biotech staff will continue their work and scientific journey in Embark Laboratories. [ EMBARK Laboratories is a spin-out from EMBARK Biotech, ww230901 ] *

 

	Start	2017-01-01 splitoff
	Group	Novo Group (Group)
	Predecessor	University of Copenhagen
	Industry	obesity drug
	Person	Hansen, Casper Tind (Embark Biotech 201911 CEO + Pcovery 201307 CEO)
	Region	København (Copenhagen)
	Country	Denmark
	Street	3 Ole Maaløes Vej
	City	2200 København N
		Address record changed: 2024-01-21
Basic data	Employees	n. a.
		Record changed: 2024-02-12

Advertisement

More documents for Novo Group (Group)

• [1] CMS Hasche Sigle. (3/26/24). "Press Release: CMS Advises Sellers of Cardior Pharmaceuticals on Potential Acquisition by Novo Nordisk". Munich....
• [2] Cardior Pharmaceuticals GmbH. (3/25/24). "Press Release: Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease". Bagsværd & Hannover....
• [3] Novo Nordisk A/S. (1/4/24). "Press Release: Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases". Bagsværd, Cambridge, MA & Somerville, MA....
• [4] LimmaTech Biologics AG. (10/9/23). "Press Release: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections". Schlieren....
• [5] Novo Nordisk A/S. (9/25/23). "Press Release: Valo Health and Novo Nordisk to Collaborate to Discover and Develop Novel Treatments for Cardiometabolic Diseases Using Human Data and Artificial Intelligence". Bagsværd & Boston, MA....
• [6] Embark Laboratories ApS. (8/30/23). "Press Release: Novo Nordisk Acquires Embark Biotech, including Its Lead Asset Targeting Obesity and other Cardiometabolic Diseases". Copenhagen....
• [7] Novo Nordisk A/S. (8/10/23). "Press Release: Novo Nordisk to Acquire Inversago Pharma to Develop New Therapies for People Living with Obesity, Diabetes and other Serious Metabolic Diseases". Bagsværd & Montreal....
• [8] Bactolife A/S. (8/8/23). "Press Release: Bactolife Raises EUR 30 Million in Series A Financing". Copenhagen....
• [9] BioGeneration Ventures B.V.. (7/13/23). "Press Release: BioGeneration Ventures Closes BGV Fund V at €150 Million". Naarden....
• [10] EQT AB. (6/21/23). "Press Release: EQT Private Equity to Sell Ellab, Following Transformation into a Leading Validation & Monitoring Provider for the Biotech and Pharmaceutical Industries"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.